NRx Pharmaceuticals, Inc.
NRXP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $23,137 | $34,850 | $730,014 | $2,242,680 |
| - Cash | $1,443 | $4,595 | $20,054 | $27,605 |
| + Debt | $6,577 | $9,161 | $10,525 | $518 |
| Enterprise Value | $28,271 | $39,416 | $720,485 | $2,215,593 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$5 | -$5 | -$4 | -$2 |
| % Margin | – | – | – | – |
| EBITDA | -$24,042 | -$30,025 | -$39,750 | -$93,043 |
| % Margin | – | – | – | – |
| Net Income | -$25,126 | -$30,150 | -$39,754 | -$93,063 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.39 | -3.98 | -0.6 | -7.44 |
| % Growth | 39.9% | -563.3% | 91.9% | – |
| Operating Cash Flow | -$10,637 | -$21,657 | -$39,755 | -$37,703 |
| Capital Expenditures | $0 | -$3 | -$10 | -$7 |
| Free Cash Flow | -$10,637 | -$21,660 | -$39,765 | -$37,710 |